Glipizide tablet

Warnings

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY:
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetics Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups. (Diabetes, 19, supp. 2:747-830, 1970).
UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glipizide and of alternative modes of therapy.
Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.



Inactive ingredient

INACTIVE INGREDIENTS:

COLLOIDAL SILICON DIOXIDE


CROSCARMELLOSE SODIUM


ANHYDROUS LACTOSE


CELLULOSE, MICROCRYSTALLINE


STARCH, CORN


STEARIC ACID



Ingredients and appearance - Product information

Glipizide tablet- Glipizide

Product information

Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC: 49349-719
Route of Administration Oral

Active Ingredient/Active Moiety

Ingredient Name Strength
Glipizide ( UNII: X7WDT95N5C)( Glipizide - UNII: X7WDT95N5C ) 10 mgin 1

Inactive Ingredients

Ingredient Name Code
Silicon dioxide ( UNII: ETJ7Z6XBU4)
Croscarmellose sodium ( UNII: M28OL1HH48)
Anhydrous lactose ( UNII: 3SY5LH9PMK)
Cellulose, microcrystalline ( UNII: OP1R32D61U)
Starch, corn ( UNII: O8232NY3SJ)
Stearic acid ( UNII: 4ELV7Z65AP)

Product Characteristics

Color white Score 2
Shape ROUND (TABLET) Imprint Code WATSON;461
Size 10 mm

Packaging

# Item Code Package Description Marketing Start Date
1 NDC: 49349-719-02 30 in 1 BLISTER PACK 2011/05/16

Marketing Information

Marketing Category Application Number or Monograph Citation Territorial Authority Marketing Start Date
ANDA ANDA074223 USA 2011/05/16

Labeler - REMEDYREPACK INC.( 829572556)